Lung cancer in 2010: One size does not fit all.

Lovly CM, Carbone DP
Nat Rev Clin Oncol. 2011 8 (2): 68-70

PMID: 21278771 · DOI:10.1038/nrclinonc.2010.224

Advances in non-small-cell lung cancer over the past decade have resulted in new treatments with minimal toxic effects and dramatic clinical benefits. 2010 saw continued advancement in our understanding of the molecular genetics of lung cancer and of specific targeted inhibitors with remarkable clinical benefit in selected populations.

MeSH Terms (5)

Antineoplastic Agents Biomarkers, Tumor Humans Lung Neoplasms Time Factors

Connections (1)

This publication is referenced by other Labnodes entities: